276 related articles for article (PubMed ID: 25548321)
41. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.
Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R
Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790
[TBL] [Abstract][Full Text] [Related]
42. TOX expression in cutaneous B-cell lymphomas.
Schrader AM; Jansen PM; Willemze R
Arch Dermatol Res; 2016 Aug; 308(6):423-7. PubMed ID: 27180090
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
44. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS).
Jothishankar B; Venkataraman G; Goldberg RC; Abdulla F
Ann Diagn Pathol; 2019 Dec; 43():151404. PubMed ID: 31629155
[No Abstract] [Full Text] [Related]
45. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
46. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
47. c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.
Wu J; Salva KA; Wood GS
J Invest Dermatol; 2015 Mar; 135(3):861-868. PubMed ID: 25140833
[TBL] [Abstract][Full Text] [Related]
48. Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.
Gallardo F; Bertran J; López-Arribillaga E; González J; Menéndez S; Sánchez I; Colomo L; Iglesias M; Garrido M; Santamaría-Babí LF; Torres F; Pujol RM; Bigas A; Espinosa L
Leukemia; 2018 Oct; 32(10):2211-2223. PubMed ID: 29511289
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.
Kiessling MK; Klemke CD; Kaminski MM; Galani IE; Krammer PH; Gülow K
Cancer Res; 2009 Mar; 69(6):2365-74. PubMed ID: 19258503
[TBL] [Abstract][Full Text] [Related]
50. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
52. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
Kopp KL; Kauczok CS; Lauenborg B; Krejsgaard T; Eriksen KW; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N; Woetmann A
Leukemia; 2010 Jun; 24(6):1179-85. PubMed ID: 20428208
[TBL] [Abstract][Full Text] [Related]
53. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
54. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
Nikolova M; Bagot M; Boumsell L; Bensussan A
Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma.
Peru S; Prochazkova-Carlotti M; Cherrier F; Velazquez J; Richard E; Idrissi Y; Cappellen D; Azzi-Martin L; Pham-Ledard A; Beylot-Barry M; Merlio JP; Poglio S
J Invest Dermatol; 2022 Dec; 142(12):3243-3252.e10. PubMed ID: 35850209
[TBL] [Abstract][Full Text] [Related]
57. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
58. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
59. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.
Lee CS; Ungewickell A; Bhaduri A; Qu K; Webster DE; Armstrong R; Weng WK; Aros CJ; Mah A; Chen RO; Lin M; Sundram U; Chang HY; Kretz M; Kim YH; Khavari PA
Blood; 2012 Oct; 120(16):3288-97. PubMed ID: 22936659
[TBL] [Abstract][Full Text] [Related]
60. Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.
Fujii K; Karpova MB; Asagoe K; Georgiev O; Dummer R; Urosevic-Maiwald M
Leukemia; 2015 Oct; 29(10):2024-32. PubMed ID: 25915825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
